Teva and Celltrion Launch Herzuma (biosimilar, trastuzumab) in the US

Teva and Celltrion Launch Herzuma (biosimilar, trastuzumab) in the US

Shots:

  • Teva and Celltrion report the availability of Herzuma (trastuzumab-pkrb), a biosimilar referencing Herceptin in the US. The biosimilar is designed to treat the same indications as to reference product relating to breast cancer and gastric cancer
  • The drug will be available at WAC of $1,402.50 for a 150mg dosage and $3,927 for a 420mg dosage, representing a 10% discount on the WAC of Herceptin
  • Herzuma (trastuzumab-pkrb) is a biosimilar referencing Herceptin, with no differences in safety, purity and potency. In Oct’2016, the companies signed an exclusive partnership to commercialize Herzuma in the US & Canada

Click here ­to­ read full press release/ article | Ref: Teva  | Image:  Celltrion